Medicalcv (MM) (NASDAQ:MDCV)
Historical Stock Chart
From Jun 2019 to Jun 2024
![Click Here for more Medicalcv (MM) Charts. Click Here for more Medicalcv (MM) Charts.](/p.php?pid=staticchart&s=N%5EMDCV&p=8&t=15)
MedicalCV Announces Information to Be Available Through S&P
Market Access Program
MINNEAPOLIS, May 2 /PRNewswire-FirstCall/ -- MedicalCV, Inc. (OTC:MDCV)
(BULLETIN BOARD: MDCV) , http://www.medcvinc.com/ , a cardiovascular surgery
device manufacturer, focusing on the surgical needs surrounding atrial
fibrillation, announced today that its company information will be made
available via Standard & Poor's Market Access Program, an information
distribution service that enables subscribing publicly traded companies to have
their company information disseminated to users of Standard & Poor's Advisor
Insight. The company information to be made available through this program
includes share price, volume, dividends, shares outstanding, company financial
position, and earnings. Standard & Poor's Advisor Insight is an Internet-based
research engine used by more than 100,000 investment advisors. A public version
of the site is available at http://www.advisorinsight.com/ .
In addition, information about companies in Standard & Poor's Market Access
Program will be available via S&P's Stock Guide database, which is distributed
electronically to virtually all-major quote vendors. As part of the program, a
full description of MedicalCV, Inc. will also be published in the Daily News
section of Standard Corporation Records, a recognized securities manual for
secondary trading in approximately 37 states under the Blue Sky Laws.
About MedicalCV, Inc.
MedicalCV, Inc., a cardiovascular surgery device manufacturer, focuses on the
design, development and commercialization of new, improved and enhanced
technologies, products, methods and techniques to treat cardiovascular
disorders and disease, including products targeting the treatment of atrial
fibrillation ("AF"). Historically, MedicalCV developed and marketed
Omnicarbon(R) mechanical heart valves utilizing its proprietary pyrolytic
carbon processes. As of April 2005 the Company ceased marketing mechanical
heart valves to focus on products for the treatment of AF. The Company's core
technology is the ATRILAZE(TM) Surgical Ablation System, for use in cardiac
tissue ablation in surgery, which the Company acquired on August 27, 2003 and
for which it received FDA 510(k) clearance on November 30, 2004. The Company's
common stock is traded on the OTC Bulletin Board under the symbol "MDCV."
For further information on MedicalCV, Inc., please visit
http://www.medcvinc.com/ .
You may register to receive MedicalCV's future press releases and to be added
to the Company's distribution list by visiting: http://www.roiny.com/form.php .
Company information distributed through the Market Access Program is based upon
information that Standard & Poor's considers to be reliable, but neither
Standard & Poor's nor its affiliates warrant its completeness or accuracy, and
it should not be relied upon as such. This material is not intended as an
offer or solicitation for the purchase or sale of any security or other
financial instrument.
MedicalCV, Inc. Contact:
John H. Jungbauer
Vice President, Finance and CFO
Phone 651.452.3000
http://www.medcvinc.com/
Investor Relations Contact:
ROI Group Associates, Inc.
Robert Giordano / Sarah Shepard
President / Vice President
Phone 212.495.0200, ext. 10 / 17
/
http://www.roiny.com/
DATASOURCE: MedicalCV, Inc.
CONTACT: John H. Jungbauer, Vice President, Finance and CFO of
MedicalCV, Inc., +1-651-452-3000, , or Investor
Relations, Robert Giordano, President, +1-212-495-0200 ext. 10,
, or Sarah Shepard, Vice President,
+1-212-495-0200 ext. 17, , both of ROI Group Associates,
Inc.
Web site: http://www.medcvinc.com/
http://www.advisorinsight.com/
http://www.roiny.com/form.php